Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension (OLMETREAT)

NCT00311155 Phase 4 COMPLETED Results posted

This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.

Details

Lead sponsor	Sankyo Pharma Gmbh
Phase	Phase 4
Status	COMPLETED
Enrolment	694
Start date	2006-03
Completion	2008-04

Conditions

• Essential Hypertension

Interventions

• olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

Primary outcomes

• The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved. — Baseline to ≤20 weeks
  For non-diabetic participants the target seated blood pressure goals were: Systolic - ≤130 mm Hg; Diastolic - ≤85 mm Hg. For diabetic participants the target seated blood pressure goals were: Systolic - \<130 mm Hg; Diastolic - \<80 mm Hg.

Countries

Austria, Belgium, France, Germany, Italy, Netherlands, Portugal, Switzerland, United Kingdom